namodenoson (CF102)

The same experiment on mice fed a lean diet demonstrated no namodenoson effect (mean weight: 33.5 ± 3.9 vs 33.0 ± 0.6 g, respectively). In conclusion, our findings support continued investigation of namodenoson as a weight-loss drug candidate.

P3, N=471, Recruiting, Can-Fite BioPharma | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P2, N=20, Recruiting, Can-Fite BioPharma | Not yet recruiting --> Recruiting

P2, N=20, Not yet recruiting, Can-Fite BioPharma | Initiation date: Jul 2024 --> Dec 2024

P2, N=114, Recruiting, Can-Fite BioPharma | Phase classification: P2b --> P2

P2, N=20, Not yet recruiting, Can-Fite BioPharma

Subsequently, inhibition of liver inflammation, steatosis, and fibrosis were documented in MASH experimental models, and inhibition of HCC growth was observed in vitro, in vivo, and in clinical studies. This review discusses the evidence related to the multifaceted mechanism of action of namodenoson, and how this mechanism is reflected in the available clinical data in MASH and HCC.

P3, N=471, Recruiting, Can-Fite BioPharma | Not yet recruiting --> Recruiting

This case report demonstrates that treatment with namodenoson can lead to a complete and durable response in patients with HCC and CPB7. Figure: CT images of the tumor at baseline as well as 7 weeks and approximately 5 years after treatment initiation

It was found that 2‑Cl‑IB‑MECA enhanced carboplatin and doxorubicin cytotoxic effects in the JoPaca‑1 and Hep‑3B cell lines, and a greater synergy was found in the highly tumorigenic JoPaca‑1 cell line...Other currently used conventional chemotherapeutics, fluorouracil and gemcitabine, showed synergy only when combined with high doses of 2‑Cl‑IB‑MECA. Notably, experiments with AAR‑specific antagonist, N‑[9‑Chloro‑2‑(2‑furanyl)(1,2,4)‑triazolo(1,5‑c)quinazolin‑5‑yl]benzene acetamide, revealed that 2‑Cl‑IB‑MECA had antitumor effects via both A3AR‑dependent and ‑independent pathways. In conclusion, the present study identified novel antitumor mechanisms of 2‑Cl‑IB‑MECA in pancreatic and hepatocellular carcinoma in vitro that further underscores the importance of A3AR agonists in cancer therapy.